Navigation Links
Millennium Announces VELCADE(R) (Bortezomib) for Injection First-Quarter 2008 U.S. Net Sales
Date:4/9/2008

lennium and Ortho Biotech Inc. are co-promoting VELCADE in the U.S. VELCADE is approved in over 85 countries worldwide. More than 85,000 patients have been treated with VELCADE globally.

In the U.S., VELCADE is indicated for the treatment of patients with multiple myeloma who have received at least one prior therapy. VELCADE is also indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. VELCADE is contraindicated in patients with hypersensitivity to bortezomib, boron, or mannitol. VELCADE should be administered under the supervision of a physician experienced in the use of antineoplastic therapy. In the European Union and many other countries worldwide, VELCADE is approved for patients with multiple myeloma after first relapse.

Risks associated with VELCADE therapy include new or worsening peripheral neuropathy, hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor peripheral neuropathy have been reported. The long-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma. Acute development or exacerbation of congestive heart failure, and/or new onset of decreased left ventricular ejection fraction has been reported, including reports in patients with few or no risk factors for decreased left ventricular ejection fraction. There have been rare reports of acute diffuse infiltrative pulmonary disease of unknown etiology such as pneumonitis, interstitial pneumonia, lung infiltration and Acute Respiratory Distress Syndrome in patients receiving VELCADE. Some of these events have been fatal. A higher proportion of these events have been reported in Japan. There have been rare reports of Reversible Posterior Leukoencephalopathy Syndrome (RPLS
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Millennium Announces $200,000 Purchase Order From Greek Distributor
2. Millennium Biotechnologies, Inc. Signs Marketing and Distribution Agreement with Ferring Pharmaceuticals
3. Millennium Over-Delivers on 2007 Goals and Financial Guidance
4. Millennium Biotechnologies Group Reports 40% Sales Increase for Resurgex Product Line in Greek Market
5. Millennium Announces 2008 Goals for Growth, Building on Record 2007 Results
6. Millennium to Receive $40 Million Milestone Payment for Achievement of Sales Threshold for Velcade(R) (Bortezomib) for Injection
7. Millennium Ships and Records the First $200,000 of Revenue Generated From the Five-Year $20,000,000 Exclusive Purchase Order
8. Millennium Biotechnologies, Inc. Launches SURGEX(TM) the First Scientifically Validated Sports Nutritional Product Created from the Medical Markets
9. Millennium Research Group Offers New Marketrack Service that Tracks European Dental Implant Market
10. Millennium Reports Outstanding Third-Quarter Results Driven by VELCADE(R) (Bortezomib) for Injection Sales
11. Millennium to Webcast Third-Quarter 2007 Financial and Operational Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... VILLAGE, Nev. , March 4, 2015 PDL BioPharma, ... the adjusted conversion rate for the: , 3.75% ... is 174.8506 shares of common stock per $1,000 principal amount ... The conversion rate for the note is adjusted in ... paid on March 12, 2015, to all stockholders who own shares ...
(Date:3/4/2015)... March 4, 2015 In an article published ... Center for Health Security review the clinical aspects of ... used as bioweapons. The article, "Clinical Management of Potential ... the website of the New England Journal of ... Eric Toner , and Tom Inglesby—review the clinical management ...
(Date:3/4/2015)... BALTIMORE , March 4, 2015 The ... of its 2015 Fellows in the Emerging Leaders in ... fostering future leaders in the field of biosecurity, UPMC ... biosecurity from a wide array of backgrounds, including biological ... private sector. "With the vision and ...
(Date:3/4/2015)... , March 4, 2015  Brooklyn residents now have ... and chronic pain and injuries. Nunzio Saulle , ... grand opening of his NJS Physical Medicine and Rehabilitation ... on Thursday, March 5, 2015. Health Plus Management, LLC ... is located at 1178 Flatbush Avenue. This new PM&R ...
Breaking Biology Technology:PDL BioPharma Announces Conversion Rate Adjustment for Convertible Note 2Latest Clinical Information On Bioterrorism Threats 2UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity 2UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity 3NJS Physical Medicine & Rehabilitation Opening on Flatbush Avenue, Brooklyn, NY 2
... PRINCETON, N.J., Feb. 27 Pharmasset, Inc.,(Nasdaq: ... Group,s,Second Annual SIGnificant Investment Options in Healthcare Conference ... in New York, NY. Schaefer Price,Pharmasset,s Chief Executive ... Wednesday, March 5, 2008 from 2:00 PM to ...
... Agreement gives ReachBio exclusive North American distribution rights to, ... products for drug ... applications, SEATTLE, Feb. 27 ReachBio LLC (Seattle, ... line of Axiogenesis AG,(Cologne, Germany) to the North American ...
... Access to ZFN Technology To Potentially Improve ... ... SGMO ) today announced that it has entered into a,second ... to include additional targets for potential improvement,of production cell lines using ...
Cached Biology Technology:Pharmasset to Present at Susquehanna's Second Annual SIGnificant Investment Options in Healthcare Conference on Wednesday, March 5th 2ReachBio Partners with Axiogenesis to Distribute Novel Cell-Based Products in North America 2ReachBio Partners with Axiogenesis to Distribute Novel Cell-Based Products in North America 3Sangamo BioSciences Announces Expansion of Research and License Agreement With Genentech for ZFP Technology for Protein Pharmaceutical Production 2Sangamo BioSciences Announces Expansion of Research and License Agreement With Genentech for ZFP Technology for Protein Pharmaceutical Production 3
(Date:3/4/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/48tj8z/global_biometrics ) ... Biometrics Market Forecast and Opportunities, 2020" report ... biometric authentication systems is projected to grow at ... The driving forces for this highly competitive ... and constant development in technology. In 2014, government ...
(Date:3/3/2015)... LAKE FOREST, Calif. , March 3, ... ("Company"), the leading provider of advanced cryogenic ... serving markets including immunotherapies, stem cells, cell ... health, and reproductive medicine, today announced the ... Hutchinson Cancer Research Centers, ("Fred Hutch") ...
(Date:3/2/2015)... Calif. , March 2, 2015 ... leading developer of human interface solutions, today announced ... that is designed to enable rapid and secure ... ID™ module for gaming is a turnkey solution ... the ability to quickly integrate fingerprint ID solutions ...
Breaking Biology News(10 mins):Global Biometrics Market Forecast and Opportunities, 2020 2Global Biometrics Market Forecast and Opportunities, 2020 3Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3Synaptics Unveils New Fingerprint ID Solution for Gamers 2Synaptics Unveils New Fingerprint ID Solution for Gamers 3
... organisms that feed on each other in the world,s streams ... whether the waterways flood or run dry than the amount of ... report online in the Oct. 14 issue of the journal ... in river systems will be threatened by increased variability in water ...
... global energy demands is the use of Poplar, a ... the most out of Poplar plantations, varieties that are ... or higher yields, for exampleare desired. But do these ... populations of Poplar? In particular, is the genetic makeup ...
... Calif.) A potent drug derived from an evergreen tree ... deadliest form of breast cancer. According to the National Cancer ... U.S. this year. Scientists at UC Santa Barbara, in ... mechanism by which this drug kills cancer cells. The team ...
Cached Biology News:Yale scientist helps pinpoint threats to life in world's rivers 2The risks and benefits of using poplars for biofuels 2UCSB scientists discover inner workings of potent cancer drug 2
6 x Blend of rTth DNA Polymerase and Tli to provide optimized amounts of both 5-3 and 3-5 proofreading activity...
... The IITC Life Science Rotarods are used ... motor coordination or fatigue resistance on mice and ... humane way. Extremely user friendly; the animals are ... an animal drops onto the individual sensing platforms ...
... Leukemia Virus Reverse Transcriptase (M-MLV RT) is an ... cDNA synthesis with long messenger RNA templates (>5kb). ... gene of M-MLV and consists of a single ... RNase H activity of M-MLV RT is weaker ...
... determination of digitonin and digoxin. Physical form: Lyophilized ... and 0.06% NaCl Preparation Note: Sodium iodide ... Res. Commun., 19, 755 (1965). Unit Definition: ... phosphorus from ATP per min at pH 7.4 ...
Biology Products: